tiprankstipranks

Keros Therapeutics announces effectiveness of global agreement with Takeda

Keros Therapeutics announces effectiveness of global agreement with Takeda

Keros Therapeutics (KROS) announced that the global development and commercialization license agreement with Takeda (TAK) to advance elritercept became effective on January 16, 2025. The agreement, which was previously announced on December 3, 2024, became effective upon the expiration or termination of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended. In connection with the effectiveness of the agreement, Takeda will make an upfront payment to the Company of $200.0 million.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue